Logo

American Heart Association

  99
  0


Final ID: MDP882

Echocardiographic Insights into Subclinical Cardiac Abnormalities in Genotype-Positive Phenotype-Negative Transthyretin (ATTR) Cardiomyopathy

Abstract Body (Do not enter title and authors here): Background: Hereditary transthyretin amyloidosis (ATTR) is often missed due to variable presentations, ranging from primarily neurologic to solely cardiac. Nearly 50% of ATTR mutation carriers develop cardiomyopathy; thus, understanding their subclinical echocardiographic abnormalities could inform early disease presentation.

Objective: Define the echocardiographic profiles of ATTR genotype-positive, cardiac phenotype-negative (Gen+/Ph-) individuals compared to matched controls and those with confirmed cardiac disease (Gen+/Ph+).

Methods: ATTR Gen+/Ph- individuals were identified based on positive genetic test and no signs of cardiac infiltration by routine echo or PYP scan. Baseline echocardiograms were analyzed and compared to age-, sex- and comorbidity-matched controls, and to Gen+/Ph+ patients with ejection fraction >50%. Structural indices, diastolic parameters and 2D strain analyses of the left ventricle (LV), left atrium (LA), right ventricle (RV) and right atrium (RA) were measured and compared for differences in rank (Mann-Whitney U test) and in effect size (Cliff’s δ).

Results: In the ATTR Gen+/Ph- group (n=39), mean age was 52±12 years, 69% were female. Mutations were V122I (23%), V30M (30%) and T60A (26%). The distribution of functional echocardiographic indices differed significantly from controls (n=78) (Table 1), with the largest effect size observed for RA reservoir strain, RV free wall longitudinal strain and LA reservoir strain (Figure 1). The proportion of ATTR Gen+/Ph- patients meeting the guidelines abnormal thresholds was different from controls for E/e’>14 (1.3% vs 10.3%), p=0.04),RV strain>-20% (1.3% vs 12.8%, p=0.02) and RA reservoir strain>-25% (1.3% vs 17.9%, p<0.01). Compared to a Gen+/Ph+ group (n=43), the distribution of all measured parameters differed significantly from the Gen+/Ph- group.

Conclusion: ATTR genetic carriers seem to be most different from controls in certain functional, rather than structural, echocardiographic indices. Longitudinal studies are needed to guide screening and early management in this population.
  • Fahed, Gracia  ( Stanford University , Palo Alto , California , United States )
  • Haddad, Francois  ( Stanford University , Palo Alto , California , United States )
  • Bagherzadeh, Shadi  ( Stanford University , Palo Alto , California , United States )
  • Jimenez, Isaiah  ( Stanford University , Palo Alto , California , United States )
  • Adrianzen Fonseca, Marina  ( University of Wisconsin School of Medicine and Public Health , Madison , Wisconsin , United States )
  • Chun, Lindsey  ( Stanford University , Palo Alto , California , United States )
  • Tang, Xiu  ( Stanford University , Palo Alto , California , United States )
  • Salerno, Michael  ( Stanford University , Palo Alto , California , United States )
  • Witteles, Ronald  ( Stanford University , Palo Alto , California , United States )
  • Alexander, Kevin  ( Stanford University , Palo Alto , California , United States )
  • Author Disclosures:
    Gracia Fahed: DO NOT have relevant financial relationships | Francois Haddad: No Answer | shadi bagherzadeh: DO NOT have relevant financial relationships | Isaiah Jimenez: DO NOT have relevant financial relationships | Marina Adrianzen Fonseca: DO NOT have relevant financial relationships | Lindsey Chun: No Answer | Xiu Tang: DO NOT have relevant financial relationships | Michael Salerno: No Answer | Ronald Witteles: DO have relevant financial relationships ; Advisor:Pfizer:Past (completed) ; Advisor:Astra Zeneca:Past (completed) ; Advisor:Alexion:Past (completed) ; Advisor:BridgeBio:Past (completed) ; Advisor:Novo Nordisk:Past (completed) ; Advisor:Alnylam:Active (exists now) | Kevin Alexander: DO have relevant financial relationships ; Consultant:Arbor Biotechnologies:Active (exists now) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Prothena:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Intellia:Past (completed) ; Consultant:Alnylam:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Unfolding Updates in Transthyretin Cardiac Amyloidosis

Sunday, 11/17/2024 , 11:10AM - 12:35PM

Moderated Digital Poster Session

More abstracts on this topic:
Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants With Transthyretin Amyloid Cardiomyopathy Compared with Placebo, Independent of Atrial Fibrillation Status

Maurer Mathew, Castano Adam, Tamby Jean-francois, Fox Jonathan, Mitter Sumeet, Hanna Mazen, Sperry Brett, Alexander Kevin, Obici Laura, Poulsen Steen, Januzzi James, Witteles Ronald, Jaber Wael, Brailovsky Yevgeniy, Vogtlaender Kai

18F-NaF and 18F-FDG and calcification predict the development of abdominal aortic aneurysms and is attenuated by drug therapy

Nakahara Takehiro, Miyazawa Raita, Iwabuchi Yu, Tonda Kai, Narula Nupoor, Strauss Harry, Narula Jagat, Jinzaki Masahiro

More abstracts from these authors:
Telehealth Use Prior to Diagnosis Associated with Earlier Transthyretin Cardiac Amyloidosis (ATTR-CM) Disease Stage

Ghaddar Jenna, Fahed Gracia, Jimenez Isaiah, Cai Nixuan, Adrianzen Fonseca Marina, Kitakata Hiroki, Haddad Francois, Witteles Ronald, Alexander Kevin

Commentary: Mab Therapy for Cardiac Amyloid

Alexander Kevin, Witteles Ronald

You have to be authorized to contact abstract author. Please, Login
Not Available